1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

In Brief: FTC, FDA Enforcement; Insider Trading On NBTY Sale; Comment Period On Label Changes

 
• By Elizabeth Crawford

FTC says Pure Green Coffee perks false claims; NBTY shareholder settles insider trading case; scientific citations trigger warning letter; supplement labels must detail plant source; scientific citations trigger warning; and more news In Brief.

The Federal Trade Commission alleges NBP Advertising Inc.’s Pure Green Coffee business makes false claims about a self-named supplement and creates fake blogs and news sites to promote the weight loss product, according to a May 19 announcement. In addition, NBP misappropriated logos from actual news organizations, including CNN, to confuse consumers about whether they are viewing an advertisement or news piece, according to FTC’s complaint filed in the U.S. District Court for the Middle District of Florida, Tampa Division. The commission also notes the Tampa-based firm failed to disclose it paid endorsers for video testimonials and provided them free product. The allegations recall an enforcement blitz that FTC brought against at least 10 affiliate marketers of acai supplements in 2011 for faking news investigations to advertise their supplements Also see "FTC Continues Acai Crackdown With Blitz Against Affiliate Marketers" - Pink Sheet, 25 April, 2011..

A former [NBTY Inc.] board member and some of his family members agree to pay $500,000 to resolve allegations of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

US FDA Pediatric Adcomm To Examine HPV, Flu, Dengue Vaccines: No News Is Good News?

 
• By Sue Sutter

Pediatric Advisory Committee will weigh the FDA's recommendation that routine safety monitoring continue for Merck & Co's Gardasil and Sanofi's Fluzone and Dengvaxia despite a political climate that has been unkind to vaccines.

Medicaid Changes Could Have Major Impact on Recent Coverage Improvements

 
• By Tim Casey

Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.

Drug Sponsors Can Help Shape Agenda For FDA/EMA Pediatric ‘Cluster’ Calls

 
• By Sue Sutter

Companies can propose specific issues for discussion during the regulators’ monthly teleconferences, which focus on finding areas of agreement and reasons for nonalignment on specific pediatric development plans or general issues.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

More from North America

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.